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Background: To compare the prognosis of upper urinary tract (UUT)-urothelial carcinoma (UC) and UC of the
bladder (UCB) by pathological staging in patients treated with radical surgeries.
Methods: The study population comprised 335 and 302 consecutive radical surgery cases performed between 1991
and 2010 for UUT-UC and UCB, respectively. Five-year recurrence-free survival (RFS) and cancer-specific survival
(CSS) rates were analyzed. The median follow-up period of all subjects was 59.3 months (range, 0.1–261.0 months).
Results: No difference was observed in median patient age, distribution of pathologic T stage, or rates of positive
surgical margin between the two groups. The UUT-UC group had significantly more frequent hydronephrosis than
the USB group (48.1% vs. 20.2%, p < 0.001). However, the UUT-UC group showed significantly less frequent grade III
tumors (28.1% vs. 58.6%, p < 0.001), lymphovascular invasion (18.8% vs. 35.8%, p < 0.001), and associated carcinoma
in situ (9.0% vs. 21.9%, p < 0.001) than the UCB group. Five year RFS rates in the UUT-UC and UCB groups were
77.0% and 75.9%, respectively (p = 0.546). No significant difference in RFS rate was observed between pathological T
stage subgroups. Five year CSS rates in the UUT-UC and UCB groups were 76.1% and 76.2%, respectively (p = 0.462).
No significant difference was observed in CSS rate between the pathologic T stage subgroups.
Conclusions: UUT-UC and UCB showed comparable prognosis at identical stages. However, our results should be
verified in a prospective study due to the retrospective study design in this study.
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PrognosisBackground
Urothelial carcinoma (UC) is the fourth most common
tumor in the United States and Europe, representing a
heterogeneous groups of cancers [1]. UC can be located
in any urothelial epithelia of the entire urinary tract. UC
of the bladder (UCB) is the most common type of UC,
accounting for 95%. Upper urinary tract (UUT)-UC rep-
resents 5% of UC at the initial diagnosis [2]. A 30–51%* Correspondence: kuuro70@snu.ac.kr
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unless otherwise stated.risk of bladder recurrence within 5 years was reported
for patients who underwent radical nephroureterectomy
for UUT-UC [3], with a 2–6% risk of developing a sub-
sequent UUT-UC after UCB [4].
The two types of UC share common pathogenic mecha-
nisms. They are expected to show analogous tumor char-
acteristics [5] with similar prognostic risk factors [6,7].
However, although pathological staging of the two types of
tumors is based identically on the natural anatomy of the
UUT and the bladder, there have been some concerns that
UUT may be more vulnerable to tumor spreading com-
pared to that of the urinary bladder. The thinner muscleis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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channels [9] of the UUT are postulated to make tumor
invasion and metastasis easier than those in UCB. In
fact, it was reported UUT-UC was more invasive and
metastatic than that of UCB at initial diagnosis [10],
with 60% of UUT-UC as invasive at diagnosis compared
to only 15% of UCB. There is strong clinical, etiological,
epidemiological, and genetic evidence that UUT-UC
and UCB should be considered distinct urothelial
entities [11].
Currently, it is not clear whether the prognoses of
these two types of UC are different for identical patho-
logical staging. Therefore, we designed this study to
compare the prognosis of UUT-UC and UCB by staging
patients treated with radical surgery.Methods
Patient selection
This study protocol was approved by the institutional re-
view board of Seoul National University Hospital, Seoul,
South Korea. The study population comprised 760 con-
secutive radical surgery cases of UUT-UC or UCB per-
formed between 1991 and 2010 at our institution
(Figure 1). Of the 760 cases, 37 (9.7%) of radical
nephroureterectomy cases and 64 (17.0%) of radical cyst-
ectomy cases were excluded from analysis. The reasons
for exclusion are shown in Figure 1. Since there was a
possibility of pathologic downstaging in patients who re-
ceived neoadjuvant chemotherapy, we excluded 38 pa-
tients who received neoadjuvant. Thereafter, 11 (1.7%) of
the remaining cases were identified to receive concomi-
tant radical nephroureterectomy and radical cystectomy.Figure 1 Patient selection.Therefore, 335 patients with UUT-UC and 302 with
UCB were analyzed in the current study.Treatments and follow-up
The workup, surgery, pathological review, and follow-
up have been described in details previously [12,13].
Lymph node dissection (LND) was conducted in select-
ive cases in the UUT-UC group that were suspicious for
metastatic nodes based on preoperative evaluation. The
extent of LND was decided by the surgeon. Radical cyst-
ectomy with pelvic LND was routinely performed in
cases of muscle invasive UCB (pT ≥ 2), pT1 with con-
current carcinoma in situ (CIS), recurrence after intra-
vesical Bacille Calmette-Guérin (BCG) immunotherapy,
or with variant histologic subtypes such as micropapil-
lary form. The extent of pelvis LND was limited below
the bifurcation of common iliac vessels in most patients.
A few patients underwent LND above the iliac
bifurcation.
Excised specimens were processed according to stand-
ard pathological procedures. Tumor-node-metastasis
staging of the tumor was classified by the 6th revised
recommendation of the American Joint Cancer Com-
mittee 2002 [14]. Tumor grade was assessed based on
the 1973 World Health Organization classification.
Tumor recurrence was defined as local failure at the op-
erative site, regional LNs, or distant metastasis at
follow-up evaluations. Lymphovascular invasion (LVI)
was defined as positive tumor cells in the vessel-like
endothelium-lined space without the muscular wall.
Cause of death was determined by the clinician based
on chart review and authorized death certificate.
Table 1 Patient characteristics
Upper urinary
tract cancer











Male 265 79.1 270 89.4
Female 70 20.9 32 10.6




1 114 34.0 136 45.0
≥2 221 66.0 166 55.0
Hydronephrosis 161 48.1 61 20.2 <0.001
Pathological T category 0.584
≤pT1 131 39.1 113 37.4
pT2 58 17.3 62 20.5
≥pT3 146 43.6 127 42.1
Pathological N category <0.001
pN- 39 11.6 237 78.5
pN+ 16 4.8 65 21.5
pNx 280 83.6 0 0.0
Tumor grade <0.001
≤II 241 71.9 125 41.4
III 94 28.1 177 58.6
LVI 63 18.8 108 35.8 <0.001
Associated CIS 30 9.0 66 21.9 <0.001
Positive surgical margin 14 4.2 23 7.6 0.064
Abbreviations: ASA = American Society of Anesthesiologists, LVI = Lymphovascular
invasion, CIS = carcinoma in situ.
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Statistical analyses
Five-year recurrence-free survival (RFS) and cancer-
specific survival (CSS) rates were analyzed. Kaplan–
Meier curve and log-rank analyses were applied to com-
pare survival in the two groups. The prognostic factors
assessed were: tumor location (UUT vs. bladder), age,
sex, body mass index (BMI), American Society of Anes-
thesiologists (ASA) score, presence of hydronephrosis,
pathological T stage, pathological N stage, tumor grade,
LVI or associated CIS, and margin status. All significant
variables in the univariate analysis were included in
a multivariate Cox model. Statistical analysis was
performed using SPSS (SPSS Inc., Chicago, IL, USA). All
tests were two-tailed with a significance level considered
when p value was less than 0.05.
Results
The descriptive characteristics of the 335 UUT-UC and
302 UCB patients are summarized in Table 1. The me-
dian follow-up for all subjects was 59.3 months (range,
0.1–261.0 months). Of the 302 UCB patients, 36 (10.5%)
had no residual tumor (pT0). No difference in median
age or pathologic T stage distribution was observed be-
tween the two groups. The two types of tumors were
male dominant (79.1% vs. 89.4%, p < 0.001). The UUT-
UC group had significantly higher BMI (24.2 vs. 23.4,
p = 0.001), higher ASA score ≥ 2 (66.0% vs. 55.0%,
p = 0.005), and more frequent hydronephrosis (48.1% vs.
20.2%, p < 0.001) than the UCB group. However, the
UUT-UC group showed less frequent grade III tumors
(28.1% vs. 58.6%, p < 0.001), LVI (18.8% vs. 35.8%,
p < 0.001), and associated CIS (9.0% vs. 21.9%, p < 0.001)
than the UCB group. There was no difference in the rate
of positive surgical margins between the two groups
(4.2% vs. 7.6%, p = 0.064).
The Kaplan–Meier curves for RFS of the two groups
stratified into three pathologic T stage subgroups are
shown in Figure 2. Five year RFS rates of the UUT-UC
and UCB groups were 77.0% and 75.9%, respectively
(p = 0.546) (Figure 2A). No significant difference in RFS
rate was observed among pathologic T stage subgroups
(Figure 2B–D).
Univariate and multivariate analyses to predict RFS in
all patients after radical surgery are summarized in
Table 2. In the univariate analysis, BMI, presence of
hydronephrosis, pathological T stage, pathological N
stage, tumor grade, LVI, and positive surgical margin
were highly significant predictors of recurrence. In the
multivariate analysis including those parameters, patho-
logical T stage (pT2, hazard ratio [HR]: 2.88, 95% confi-
dence interval [CI]: 1.57–5.26, p = 0.001; ≥ pT3, HR:4.68, 95% CI: 2.74–7.99, p < 0.001), pathological N stage
(HR: 1.85, 95% CI: 1.18–2.89, p = 0.007), and LVI (HR:
1.50, 95% CI: 1.04–2.15, p = 0.029) remained independ-
ent predictors of recurrence. However, tumor location
(UUT vs. bladder) did not affect RFS.
Five year CSS rates of the UUT-UC and BCB groups
were 76.1% and 76.2%, respectively (p = 0.462)
(Figure 3A). No significant difference in CSS rate
was observed among pathologic T stage subgroups
(Figure 3B–D).
Cox models used to predict CSS are shown in Table 3. In
the univariate analysis, age, BMI, hydronephrosis, patho-
logical T and N stage, tumor grade, LVI, and positive surgi-
cal margin were significant predictors of cancer-specific
Figure 2 Kaplan–Meier curves for recurrence-free survival (RFS) in patients with upper urinary tract urothelial carcinoma (UUT-UC) and
urothelial carcinoma of bladder (UCB). Between UUT-UC and UCB groups, no significant in 5 year-RFS rates were observed in (A) overall pathologic T
stages (77.0% vs. 75.9%, p = 0.546), (B) pathological T stage≤ 1 (93.3% vs. 93.2%, p = 0.309), (C) pathological T stage = 2 (71.2% vs. 81.6%, p = 0.173), and (D)
pathological T stage≥ 3 (61.4% vs. 59.4%, p = 0.293).
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1.01–1.044, p = 0.002), hydronephrosis (HR: 1.41, 95% CI:
1.02–1.96, p = 0.041), pathological T stage (pT2, HR: 2.71,
95% CI: 1.50–4.88, p = 0.001; ≥ pT3, HR: 4.96, 95% CI:
2.94–8.36, p < 0.001), pathological N stage (pN, HR: 1.99,
95% CI: 1.28–3.07, p = 0.002), and LVI (HR: 1.66, 95% CI:
1.16–2.37, p = 0.005) were independent predictors. Tumor
location was not a predictor of CSS.
Discussion
UC can develop in a synchronous or metachronous
multifocal manner at different urinary tract sites. Due to
the relative preponderance of UCB, much of the clinical
decision making regarding UUT-UC is extrapolated
from evidence gained on UCB. However, because
UUT-UC is biologically unique with appreciable genetic,
molecular, and clinical differences from UDB [15], it re-
mains questionable whether UCB findings could be
safely extrapolated to UUT-UC.Patients with UUT-UC generally have more advanced
disease at the initial diagnosis [10,16]. Stewart et al. re-
ported that tumor grade ≥ 3 (44% vs. 35%, p = 0.003) and
pathologic T stage ≥ 2 (33% vs. 20%, p = 0.001) were
more frequent in UUT-UC than those in UCB [16].
Several hypotheses have been proposed for the different
tumor behavior of UUT-UC compared to UCB. Thinner
muscle layer structure [8] and abundant lymphatic and
blood channels [9] of UUT have been postulated to
make tumor invasion or metastasis easier in patients
with UUT-UC. These anatomical features of UUT repre-
senting thinner muscle/adventitia layer and smaller cali-
ber lumen, can cause hardship to ensure sufficient
healthy tissue for a safe surgical margin following con-
servative UUT-UC surgery [17]. Therefore, technical
limitations of UUT-UC sampling compared to trans-
urethral resection for bladder tumors may be the most
important cause of staging differences between UUT-UC
and UCB. Aside from these anatomical characteristics
Table 2 Univariate and multivariate Cox proportional hazard regression analyses of recurrence-free survival
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Tumor location
Upper urinary tract vs. Bladder 0.906 (0.658-1.248) 0.546
Age, years 1.016 (0.999-1.033) 0.057
Sex
Female vs. Male 1.098 (0.719-1.676) 0.665
Body mass index, kg/m2 0.947 (0.898-0.999) 0.049 0.980 (0.929-1.033) 0.453
ASA score
≥2 vs.1 0.927 (0.670-1.282) 0.645
Hydronephrosis
Present vs. Absent 1.609 (1.165-2.221) 0.004 1.378 (0.984-1.928) 0.062
Pathological T category
pT2 vs. ≤pT1 3.588 (1.992-6.461) <0.001 2.875 (1.573-5.256) 0.001
≥pT3 vs. ≤pT1 6.748 (4.087-11.141) <0.001 4.675 (2.736-7.990) <0.001
Pathological N category
pNx vs. pN- 1.174 (0.810-1.700) 0.397 1.202 (0.805-1.794) 0.369
pN+ vs. pN- 3.232 (2.113-4.942) <0.001 1.847 (1.180-2.889) 0.007
Tumor grade
III vs. ≤II 1.955 (1.416-2.699) <0.001 1.151 (0.802-1.652) 0.447
LVI
Present vs. Absent 2.639 (1.911-3.645) <0.001 1.496 (1.042-2.149) 0.029
Associated CIS
Present vs. Absent 1.054 (0.681-1.631) 0.815
Surgical margin
Positive vs. Negative 2.777 (1.675-4.605) <0.001 1.349 (0.797-2.282) 0.265
Abbreviations: HR = hazard ratio, CI = confidence interval, ASA = American Society of Anesthesiologists, LVI = Lymphovascular invasion, CIS = carcinoma in situ.
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have also been suggested as etiology of different tumor
behavior [18-21]. Hartmann et al. reported that micro-
satellite instability (MSI) present in UTT-UC was corre-
lated with mutation of human DNA mismatch repair
genes and clinicopathological characteristic of tumor
[18]. Roupret et al. also demonstrated that MSI was
rarely encountered in UCB (approximately 3%), whereas
it occurred in more than 15% of sporadic UTT-UC [19].
Catto et al. reported that the frequency of UUT-UC ap-
peared to be significantly higher than UCB (94% vs.
76%) which might be associated with the poorer clinico-
pathologic outcomes of UUT-UC [20]. Single-nucleotide
polymorphisms (SNP) variability of rs9642880[T] allele
on 8q24 and rs798766[T] allele on 4p16 was not associ-
ated with disease aggressiveness of UCB. However,
they were associated with more aggressive tumors
when stratified by stage for UTT-UC [21]. These charac-
teristics seem to make tumor invasion and metastasis
easier in patients with UUT-UC [22]. Thus, radical
nephroureterectomy with excision of the bladder cuff isrecommended as the initial treatment of choice for
high-grade UUT-UC.
However, it is still unclear whether the more aggres-
sive behavior of UUT-UC have originated from different
innate tumor biology or advanced status of the tumor at
diagnosis. Some investigators have hypothesized that if
the aggressiveness of UUT-UC is due to an initial higher
stage, the prognosis may not be different between UUT-
UC and UCB after stratification by stages. Catto et al. re-
ported that 150 UUT-UC cases and 275 UCB cases
showed similar prognoses (cancer-specific death, 35% vs.
43%) [17]. However, the population used in that study
had a different distribution of pathological T stage
(≥ pT2, 35% vs. 62%). Moreover, non-muscle invasive
UCB cases received transurethral resection of bladder
tumors, whereas all patients with UUT-UC underwent
radical nephroureterectomy. Although the authors se-
lected a subgroup of UCB patients with balanced patho-
logical status to compare the prognosis between
UUT-UC and UCB, the selection criteria were not de-
scribed clearly. In addition, the selected cases were only
Figure 3 Kaplan–Meier curves for cancer-specific survival (CSS) in patients with upper urinary tract urothelial carcinoma (UUT-UC) and
urothelial carcinoma of bladder (UCB). Between UUT-UC and UCB groups, no significant in 5 year-CSS rates were observed in (A) overall pathologic T
stages (76.1% vs. 76.2%, p = 0.462), (B) pathological T stage≤ 1 (94.4% vs. 93.8%, p = 0.296), (C) pathological T stage = 2 (71.0% vs. 80.8%, p = 0.146), and (D)
pathological T stage≥ 3 (61.1% vs. 56.4%, p = 0.142).
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fore, there may have been selection bias. Moussa et al.
[23] also found no difference in overall survival after
controlling for the effects of tumor stage. In contrast to
the study of Catto et al. [17], Moussa et al. [23] com-
pared only patients who underwent radical surgery. They
reported that patients with UCB have more advanced
pathology than those of UUT-UC cohort.
In a recent multicenter study of 4,335 patients with
UCB and 877 patients with UUT-UC, all patients were
treated with radical surgery. It was found that stage and
grade were independent predictors of CSS for the overall
cohort [24]. However, in stage-specific analyses of
patients with pT1 or less and pT4 disease, UCB and
UUT-UC were independently predictive for CSS. They
explained that the inferior outcomes of non-muscle in-
vasive UCB patients as follows, “Non-muscle invasive
UCB patients undergo radical cystectomy because of fea-
tures of aggressive biopsy. The lack of appropriate stagingand grading, poor selection leads to high rates of radical
nephroureterectomy for UUT-UC. Delay in diagnosis
and/or treatment may differentially affect outcomes in
these patients”.
Our results are in consistent with those of previous
studies [17,23]. Our subjects were comprised only of pa-
tients who received radical surgery for UUT-UC or
UCB. As a result, our two groups showed similar patho-
logical T stage characteristics (p = 0.584) (Table 1). Our
data also revealed that UUT-UC and bladder cancer had
identical 5-year RFS and CSS rates after radical surgery
in all pathological T stage stratified subgroups (Figure 2
and Figure 3).
Our study had several limitations. This study was lim-
ited by the retrospective nature of the analysis with a
relatively small number of patients. In addition, all pa-
tients with UCB underwent concomitant pelvic LND,
whereas the UUT-UC cases underwent LND in only se-
lective cases (55 of 280, 16.4%). Evidence of LND during
Table 3 Univariate and multivariate Cox proportional hazard regression analyses of cancer-specific survival
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Tumor location
Upper urinary tract vs. Bladder 0.889 (0.650-1.216) 0.462
Age, years 1.022 (1.005-1.039) 0.010 1.027 (1.010-1.044) 0.002
Sex
Female vs. Male 0.980 (0.643-1.493) 0.926
Body mass index, kg/m2 0.921 (0.874-0.971) 0.002 0.965 (0.916-1.016) 0.177
ASA score
≥2 vs.1 0.978 (0.711-1.343) 0.889
Hydronephrosis
Present vs. Absent 1.672 (1.221-2.289) 0.001 1.409 (1.015-1.957) 0.041
Pathological T category
pT2 vs. ≤pT1 3.410 (1.919-6.058) <0.001 2.707 (1.500-4.884) 0.001
≥pT3 vs. ≤pT1 7.115 (4.366-11.593) <0.001 4.960 (2.943-8.359) <0.001
Pathological N category
pNx vs. pN- 1.126 (0.784-1.619) 0.520 1.126 (0.760-1.669) 0.554
pN+ vs. pN- 3.580 (2.364-5.422) <0.001 1.986 (1.282-3.074) 0.002
Tumor grade
III vs. ≤II 1.963 (1.432-2.689) <0.001 1.105 (0.778-1.567) 0.578
LVI
Present vs. Absent 2.875 (2.098-3.938) <0.001 1.663 (1.164-2.374) 0.005
Associated CIS
Present vs. Absent 0.971 (0.624-1.512) 0.898
Surgical margin
Positive vs. Negative 3.158 (1.930-5.166) <0.001 1.483 (0.888-2.477) 0.132
Abbreviations: HR = hazard ratio, CI = confidence interval, ASA = American Society of Anesthesiologists, LVI = Lymphovascular invasion, CIS = carcinoma in situ.
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[25]. The low rate of LND in patients with UUT-UC
might lead to an undefined bias regarding clinical out-
comes. However, pelvic LND at the time of radical cyst-
ectomy is widely accepted, whereas LND at the time of
radical nephroureterectomy is performed largely at the
discretion of the surgeon, which may be due, in part, to
the variable lymphatic drainage along the course of the
ureter compared to the relatively confined lymphatic
landing sites for the bladder [26]. Our results demon-
strated that pNx was not an independent prognostic
factor for RFS (p = 0.369) or CSS (p = 0.554) when com-
pared to pN0 (Tables 2 and 3). Moreover, patients who
received neoadjuvant chemotherapy were excluded
from this study because the proportion of patients
who received neoadjuvant chemotherapy was decisively
different between the two groups. Because of the high
resemblance of UUT-UC to UCB, neoadjuvant chemo-
therapy for UUT-UC is expected to produce similar re-
sults to those seen in UCB. However, one unique
challenge for UUT-UC when incorporating neoadjuvantchemotherapy into therapy regimens is the associated
limitation to clinical staging [27]. Since limited pro-
spective data existed for neoadjuvant chemotherapy in
UUT-UC, these data are currently insufficient to pro-
vide any recommendations. Recommended policies on
neoadjuvant chemotherapy in UUT-UC and UCB are
different [28-30]. Finally, there may have been dissimi-
larities in management between patients with UUT-UC
and UCB in our cohort. Patients with pT1 or less UCB
were generally treated with transurethral resection of
the bladder tumor with or without intravesical therapy,
whereas all patients with high-grade UUT-UC were rec-
ommended to undergo radical nephroureterectomy due
to the inability to accurately stage and resect the tumor
and/or effectively deliver intracavitary therapy [26].
Conclusions
UUT-UC and UCB showed comparable prognosis at
identical stages. However, due to the retrospective study
design, our results should be verified in a prospective
study.
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